Fig. 3From: Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialMedian percentage change from baseline in spleen volume over time. *For patients in the ruxolitinib crossover group, baseline represents the date of crossover to ruxolitinib. BL, baselineBack to article page